$469 Million is the total value of BVF INC/IL's 34 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CCXI | CHEMOCENTRYX INC | $36,737,000 | +80.3% | 8,182,052 | 0.0% | 7.83% | +55.3% | |
| EXELIXIS INCnote 4.250% 8/1 | $33,935,000 | +49.3% | 22,822,778 | 0.0% | 7.23% | +28.6% | ||
| CNCE | CONCERT PHARMACEUTICALS INC | $30,942,000 | -17.8% | 2,755,318 | 0.0% | 6.59% | -29.2% | |
| OMED | ONCOMED PHARMACEUTICALS INC | $16,487,000 | +21.8% | 1,339,336 | 0.0% | 3.51% | +4.8% | |
| TBRA | TOBIRA THERAPEUTICS INC | $15,743,000 | +53.5% | 1,253,401 | 0.0% | 3.35% | +32.2% | |
| CTIC | CTI BIOPHARMA CORP | $15,231,000 | -36.0% | 44,796,940 | 0.0% | 3.24% | -44.9% | |
| XENE | XENON PHARMACEUTICALS INC | $10,511,000 | -15.3% | 1,775,572 | 0.0% | 2.24% | -27.1% | |
| GTXI | GTX INC DEL | $6,332,000 | +10.0% | 11,512,000 | 0.0% | 1.35% | -5.3% | |
| CTMX | CYTOMX THERAPEUTICS INC | $6,192,000 | -20.8% | 606,138 | 0.0% | 1.32% | -31.8% | |
| PTIE | PAIN THERAPEUTICS INC | $4,708,000 | -1.8% | 2,149,913 | 0.0% | 1.00% | -15.4% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $2,636,000 | +1.4% | 4,813,294 | 0.0% | 0.56% | -12.6% | |
| MSTX | MAST THERAPEUTICS INC | $1,738,000 | +71.6% | 3,696,961 | 0.0% | 0.37% | +47.4% | |
| CBIO | CATALYST BIOSCIENCES INC | $1,476,000 | -9.5% | 970,948 | 0.0% | 0.31% | -22.3% | |
| GBIM | GLOBEIMMUNE INC | $1,276,000 | -5.8% | 657,653 | 0.0% | 0.27% | -18.8% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 37 | Q4 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 32 | Q1 2024 | 2.8% |
| XOMA CORP DEL | 31 | Q2 2024 | 7.3% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| CYTOMX THERAPEUTICS INC | 29 | Q2 2024 | 5.3% |
| KURA ONCOLOGY INC | 28 | Q2 2024 | 5.1% |
| CORVUS PHARMACEUTICALS INC | 28 | Q1 2024 | 2.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| GLYCOMIMETICS INC | 27 | Q2 2024 | 5.7% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 4 | 2024-08-22 |
| 13F-HR | 2024-08-14 |
| 3 | 2024-08-01 |
| 4 | 2024-06-28 |
| 4 | 2024-06-18 |
| 4 | 2024-06-10 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.